Adjunctive therapy

2 papers5 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs in 1 country

Humans2

Outcomes

C-peptide

no changein humans1

1 study

Adjunctive therapy has no effect on C-peptide in humans (between-group difference 0.0202, P=0.7774).
“Adjusted mean change in fasting C-peptide was −0.0596 (95% CI: −0.160 to 0.0406) in monotherapy group and −0.0798 (95% CI: −0.178 to 0.0179) in adjunctive group (between-group difference 0.0202, P=0.7774).”
Humansclassic type 1 diabetesmedian 2.8 yearsn = 312
Effectiveness and Safety of Adjunctive Therapy in Classic Type 1 Diabetes: A Real-World Cohort Study
ADA Scientific Sessions 2026 abstract5 Jun 2026

Associations

Body mass index

upin humans1

1 study

Adjunctive therapy is associated with body mass index in humans (25.7 vs 23.1 kg/m2).
“BMI was higher in patients in the IAT vs IO groups (25.7 vs 23.1 kg/m2).”
Humansin autoimmune diabetes (RENACED-DT1 registry)
SAT-604 Use of Adjunctive Therapy in Patients With Autoimmune Diabetes In the Renaced DT1 Registry
ENDO 2025 abstract22 Oct 2025